AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Jan 10, 2023
32254_dirs_2023-01-10_aa5073f9-5047-442b-9293-df2ae1b6b3de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-01-06
Reporting Person: Duker Jay S. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-06 | Stock Option (Right to Buy) | $3.26 | A | 124755.00 | Acquired | 2033-01-05 | Common Stock (124755.00) | Direct |
Footnotes
F1: The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7